Get the Stockscreener App
2.62
0.76%
-0.02
After Hours:
2.61
-0.01
-0.38%
Mural Oncology Plc stock is traded at $2.62, with a volume of 33,956.
It is down -0.76% in the last 24 hours and up +0.00% over the past month.
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
See More
Previous Close:
$2.64
Open:
$2.6
24h Volume:
33,956
Relative Volume:
0.01
Market Cap:
$45.25M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-4.73%
1M Performance:
+0.00%
6M Performance:
-34.34%
1Y Performance:
-21.79%
1-Day Range:
$2.56
$2.709
1-Week Range:
$2.56
$2.77
52-Week Range:
$0.95
$4.74
Mural Oncology Plc Stock (MURA) Company Profile
Name
Mural Oncology Plc
Sector
Industry
Phone
353 1 905 8020
Address
10 EARLSFORT TERRACE, DUBLIN 2
Compare MURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MURA
Mural Oncology Plc
|
2.62 | 47.49M | 0 | 0 | 0 | 0.00 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Mural Oncology Plc Stock (MURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-25-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-04-24 | Initiated | Morgan Stanley | Overweight |
Mural Oncology Plc Stock (MURA) Latest News
Form 8.3Mural Oncology plc - Business Wire
BlackRock discloses stake in Mural Oncology By Investing.com - Investing.com South Africa
BlackRock discloses stake in Mural Oncology - Investing.com Australia
Goldman Sachs adjusts positions in Mural Oncology By Investing.com - Investing.com South Africa
Goldman Sachs adjusts positions in Mural Oncology - Investing.com Australia
Goldman Sachs reports trading in Mural Oncology shares By Investing.com - Investing.com South Africa
Mural Oncology Announces Number of Relevant Securities in Issue - The Manila Times
Mural Oncology Discloses Share Count Under Irish Takeover Rules: What's Behind This Move? - Stock Titan
Goldman Sachs reports trading in Mural Oncology shares - Investing.com Australia
Mural Oncology plc (NASDAQ:MURA) Shares Sold by Price T Rowe Associates Inc. MD - Defense World
Goldman Sachs reveals stake in biopharmaceutical firm Mural Oncology - Dimsum Daily
Goldman Sachs discloses stake in Mural Oncology By Investing.com - Investing.com South Africa
Goldman Sachs discloses stake in biopharmaceutical firm Mural Oncology - Dimsum Daily
Goldman Sachs discloses stake in Mural Oncology - Investing.com
Goldman Sachs reports dealings in Mural Oncology shares By Investing.com - Investing.com Nigeria
Goldman Sachs reports dealings in Mural Oncology shares - Investing.com
BlackRock discloses stake in Mural Oncology plc By Investing.com - Investing.com South Africa
BlackRock discloses stake in Mural Oncology plc - Investing.com
BlackRock reports stake in Mural Oncology By Investing.com - Investing.com Canada
BlackRock reports stake in Mural Oncology - Investing.com
56,176 Shares in Mural Oncology plc (NASDAQ:MURA) Purchased by Raymond James Financial Inc. - Defense World
Layoff Tracker: IGM Axes 80% of Workforce - BioSpace
Mural Oncology Plc Stock (MURA) Financials Data
There is no financial data for Mural Oncology Plc (MURA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):